Age at diagnosis (years) |
>60 |
59 (19.4) |
≤60 |
245 (80.6) |
Race |
White |
209 (68.8) |
Black or African American |
30 (9.87) |
Native Hawaiian or other Pacific islander |
2 (0.61) |
Asian |
20 (6.58) |
American Indian or Alaska native |
7 (2.3) |
Other |
36 (11.84) |
Clinical stage |
Stage I |
162 (53.29) |
Stage II |
69 (22.7) |
Stage III |
45 (14.8) |
Stage IV |
21 (6.91) |
Other |
7 (2.3) |
Neoplasm histologic grade |
g1 |
18 (5.92) |
g2 |
135 (44.41) |
g3 |
118 (38.82) |
g4 |
1 (0.33) |
gx |
24 (7.89) |
Other |
8 (2.63) |
HPV status |
Indeterminate |
1 (0.33) |
Negative |
22 (7.24) |
Positive |
281 (92.43) |
Menopause status |
Pre (<6 months since lmp and no prior bilateral ovariectomy and not on estrogen replacement) |
124 (40.79) |
Post (prior bilateral ovariectomy or >12 mo since lmp with no prior hysterectomy) |
82 (26.97) |
Peri (6–12 months since last menstrual period) |
25 (8.22) |
Indeterminate (neither pre or postmenopausal) |
3 (0.99) |
Other |
70 (23.03) |
Lymphovascular involvement |
Absent |
71 (23.36) |
Present |
79 (25.99) |
Other |
154 (50.65) |
Pathology T stage |
T1 |
140 (46.05) |
T2 |
71 (23.36) |
T3 |
20 (6.58) |
T4 |
10 (3.29) |
Tis |
1 (0.33) |
Tx |
17 (5.59) |
Other |
45 (14.8) |
Pathology N stage |
N0 |
133 (43.75) |
N1 |
60 (19.74) |
Nx |
66 (21.71) |
Other |
45 (14.8) |
Pathology M stage |
M0 |
116 (38.16) |
M1 |
10 (3.29) |
Mx |
128 (42.1) |
Other |
50 (16.45) |